ABBV · NYSE · STOCK
AbbVie (ABBV) Stock Analysis
$276.40
52W $190.75 – $277.60
56/100
$488.47B
77.9
0.28
Is ABBV Bullish or Bearish?
Mixed.
Innellis AI committee rates AbbVie (ABBV) Watch with a composite score of 56/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.52 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.48 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 67.6% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 95.6% shows genuine earnings power backing the valuation — Value
- Dividend yield of 4.5% pays you to wait — Value
- EPS growing 67.6% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 76.3 is expensive by classic value standards — Value
- Price-to-book of 94.4x prices in significant intangible value — Value
- Debt-to-equity of 20.19 adds balance-sheet risk to the value case — Value
- RSI at 81 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- High leverage (debt-to-equity 20.19) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
56/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 55%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · High confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ ROE of 95.6% shows genuine earnings power backing the valuation
− P/E of 76.3 is expensive by classic value standards
Growth Analyst
bullish
78
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 67.6% YoY
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 81 is in overbought territory
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 20.19) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 56.1 to 56.5.
- Committee agreement increased notably from 50% to 67%.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: News Analyst.
Analyst-level changes:
- News Analyst: stance neutral->bullish.
- Technical Analyst: +1 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
81.3
Overbought
MACD Histogram
0.958
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
1.20
Above Upper Band
Price vs Moving Averages
EMA 9
$268.82
Above
EMA 21
$265.25
Above
EMA 50
$259.34
Above
EMA 200
$237.75
Above
Fundamental Analysis
Valuation
64
Growth
72
Profitability
45
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio
77.9×
P/B Ratio
-82.50×
PEG Ratio
1.14
Dividend Yield
2.47%
52W High
$277.60
52W Low
$190.75
Quality & Growth
ROE
-12923.5%
ROA
315.5%
Gross Margin
7147.7%
Operating Margin
2932.2%
Revenue Growth YoY
—
Debt / Equity
-11.93
AI Fundamental Assessment
P/E ratio of 77.9 (rich relative to a 15-40x range); Price-to-book of -82.5x; PEG ratio of 1.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -129.2%; Return on assets of 3.2%; Net margin of 9.8%; Gross margin of 71.5%; Current ratio of 0.81 (tight short-term liquidity); Debt-to-equity of -11.93; Free cash flow per share is positive (10.28); Most recent quarter missed estimates by 0.7%; EPS growth accelerating (-2.2% -> +37.7% QoQ); Average YoY EPS growth of 22.9%; Analyst estimates rising over recent quarters
Get the Full ABBV Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →